Health and Youth Care Inspectorate – Pharmaceutical Products

CERTIFICATE NUMBER: ***NL/H 20/2016374***

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1, 2]

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:
The manufacturer: ***Curium Netherlands B.V.***
Site address: ***Westerduinweg 3, PETTEN, 1755LE, Netherlands***

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. ***108988 F*** in accordance with Art. 40 of Directive 2001/83/EC transposed in the following national legislation:
Art. 100 of the Medicines Act

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2020-01-16*** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC [3]

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

---

[1] *The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

[2] *Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

Part 2

Human Medicinal Products

1 MANUFACTURING OPERATIONS	
1.1	**Sterile products**
	1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2 Lyophilisates Special Requirements 5 Radiopharmaceuticals 1.1.1.6 Other: radionuclide generator(en)
	1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.3 Small volume liquids Special Requirements 5 Radiopharmaceuticals
	1.1.3 Batch certification
1.2	**Non-sterile products**
	1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.1 Capsules, hard shell Special Requirements 5 Radiopharmaceuticals 1.2.1.10 Radionuclide generators Special Requirements 5 Radiopharmaceuticals
	1.2.2 Batch certification
1.5	**Packaging**
	1.5.1 Primary Packaging 1.5.1.1 Capsules, hard shell Special Requirements 5 Radiopharmaceuticals 1.5.1.10 Radionuclide generators Special Requirements 5 Radiopharmaceuticals
	1.5.2 Secondary packaging

1.6	**Quality control testing**
	1.6.1 Microbiological: sterility *1.6.2 Microbiological: non-sterility* *1.6.3 Chemical/Physical* *1.6.4 Biological*

2 IMPORTATION OF MEDICINAL PRODUCTS	
2.1	**Quality control testing of imported medicinal products**
	2.1.1 Microbiological: sterility *2.1.3 Chemical/Physical* *2.1.4 Biological*
2.2	**Batch certification of imported medicinal products**
	2.2.1 Sterile products 2.2.1.1 Aseptically prepared 2.2.1.2 Terminally sterilised
2.3	**Other importation activities**
	2.3.1 Site of physical importation
	2.3.2 Importation of intermediate which undergoes further processing

Clarifying remarks (for public users)

1.6.4 and 2.1.4 are only applicable for endotoxine test

2020-03-12

Name and signature of the authorised person of the Competent Authority of Netherlands

---

Confidential
Health and Youth Care Inspectorate – Pharmaceutical Products
Tel: ***Confidential***
Fax: ***Confidential***

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of GMP and GDP certificates issued by EEA authorities is automatically extended until the end of 2024, except where clarifying remarks in the document state otherwise. Manufacturers, importers and distributors must continue to comply with GMP/GDP and all other legal obligations. On-site inspections are now being conducted and scheduling of these inspections may be independent of the extended validity period stated above. Competent authorities will continue to perform risk based supervision of sites by either on-site inspections or distant assessments and, based on the outcome, may continue to issue, withdraw or restrict GMP and GDP certificates, as appropriate.

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of GMP and GDP certificates issued by EEA authorities is automatically extended until the end of 2024, except where clarifying remarks in the document state otherwise. Manufacturers, importers and distributors must continue to comply with GMP/GDP and all other legal obligations. On-site inspections are now being conducted and scheduling of these inspections may be independent of the extended validity period stated above. Competent authorities will continue to perform risk based supervision of sites by either on-site inspections or distant assessments and, based on the outcome, may continue to issue, withdraw or restrict GMP and GDP certificates, as appropriate.